




Searching News Database: Fragile X Syndrome
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 4 Apr 2022
Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders
Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders
HSMN NewsFeed - 30 Jan 2019
ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
HSMN NewsFeed - 30 May 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 11 Aug 2015
Ovid Therapeutics Completes Oversubscribed $75 Million Series B Financing
Ovid Therapeutics Completes Oversubscribed $75 Million Series B Financing
HSMN NewsFeed - 20 Jul 2010
Seaside Therapeutics Appoints Leading Industry Executives to its Board of Directors
Seaside Therapeutics Appoints Leading Industry Executives to its Board of Directors
HSMN NewsFeed - 8 Mar 2010
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Additional items found! 5

Members Archive contains
5 additional stories matching:
Fragile X Syndrome
(Password required)
Fragile X Syndrome
(Password required)